Baidu
map

FDA批准血液癌口服药物——低甲基化制剂Inqovi

2020-07-08 MedSci原创 MedSci原创

此次批准是骨髓增生异常综合症治疗领域的重要进步,患者无需到医院接受静脉注射治疗。

大冢制药公司宣布美国食品药物管理局(FDA)批准Inqovi(decitabine/cedazuridine,胞苷脱氨酶抑制剂/地西他滨),用于治疗骨髓增生异常综合症(MDS)和慢性粒细胞单核细胞白血病(CMML)成人患者。

See the source image

图片来源:https://www.medpagetoday.com/hematologyoncology/hematology/87451

Inqovi作为口服低甲基化剂,连续五天每天服用一次,28天为一个治疗周期。此次批准是MDS治疗领域的重要进步,患者可以不需要去医院接受静脉注射治疗。

FDA药物评估和研究中心肿瘤病学办公室主任Richard Pazdur表示:“在这个关键时刻,我们将继续致力于为癌症患者提供新的选择。 ”

FDA的批准得到了Inqovi的III期ASCERTAIN研究数据的支持,该研究先前在中高危MDS成人患者中进行评估。

去年十二月,研究结果在美国血液学会(ASH)会议上发表,证明连续口服Inqovi五天与静脉注射地西他滨可以达到相似的药物浓度,从而达到了实验的主要终点。大约有一半以前依赖输血的患者在八周内不再需要输血。同时,安全性研究结果与静脉注射地西他滨一致,无临床上明显的胃肠道毒性。

原始出处:

https://www.firstwordpharma.com/node/1738563?tsid=28&region_id=6

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2060864, encodeId=e43f206086404, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38233, encryptionId=49f63823396, topicName=口服药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sat Jan 09 20:20:56 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910391, encodeId=202119103911e, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38234, encryptionId=d7cd38234fc, topicName=口服药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Tue Aug 18 21:20:56 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839845, encodeId=74d5183984590, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Jan 10 02:20:56 CST 2021, time=2021-01-10, status=1, ipAttribution=)]
    2021-01-09 gdsun
  2. [GetPortalCommentsPageByObjectIdResponse(id=2060864, encodeId=e43f206086404, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38233, encryptionId=49f63823396, topicName=口服药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sat Jan 09 20:20:56 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910391, encodeId=202119103911e, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38234, encryptionId=d7cd38234fc, topicName=口服药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Tue Aug 18 21:20:56 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839845, encodeId=74d5183984590, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Jan 10 02:20:56 CST 2021, time=2021-01-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2060864, encodeId=e43f206086404, content=<a href='/topic/show?id=49f63823396' target=_blank style='color:#2F92EE;'>#口服药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38233, encryptionId=49f63823396, topicName=口服药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Sat Jan 09 20:20:56 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910391, encodeId=202119103911e, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38234, encryptionId=d7cd38234fc, topicName=口服药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Tue Aug 18 21:20:56 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839845, encodeId=74d5183984590, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Jan 10 02:20:56 CST 2021, time=2021-01-10, status=1, ipAttribution=)]
    2021-01-10 bugit
Baidu
map
Baidu
map
Baidu
map